Novartis enters the second half of 2026 facing one of the most important periods in its recent history as investors await a series of pivotal clinical trial results that could shape the pharmaceutical giant’s growth trajectory well into the next decade. While the Swiss drugmaker’s quarterly financial results remain important, market attention is increasingly shifting toward three late-stage experimental medicines that analysts believe will determine whether Novartis can successfully navigate an approaching wave of patent expirations. With the company’s shares trading at one of the highest valuation multiples among major pharmaceutical companies, expectations for its research pipeline have rarely been higher.

Pipeline Success Becomes Increasingly Important

Novartis is preparing for key data releases from three experimental therapies targeting cardiovascular disease, multiple sclerosis, and rare genetic disorders. Analysts estimate the combined commercial opportunity for pelacarsen, remibrutinib, and del-desiran could exceed $10 billion in annual peak sales, providing a significant source of future revenue as several of the company’s largest products gradually lose market exclusivity.

Management has repeatedly emphasized innovation as the primary strategy for offsetting declining sales from established blockbuster medicines facing generic competition over the coming years. As major patent expirations approach, the success of late-stage research programs has become increasingly important in maintaining long-term earnings growth.

Investors will therefore closely examine both the timing of upcoming clinical data and management’s confidence in each program during earnings discussions.

Valuation Reflects High Expectations

Novartis currently trades at a premium valuation compared with many global pharmaceutical peers, reflecting investor optimism regarding its research pipeline and execution under Chief Executive Vas Narasimhan. However, elevated valuations also leave less room for disappointment should clinical results fail to meet expectations.

Several analysts believe the company’s current earnings multiple already incorporates a meaningful portion of the anticipated upside from its development pipeline. As a result, positive trial outcomes may reinforce investor confidence, while disappointing data could place pressure on the stock as markets reassess future growth prospects.

The pharmaceutical sector has repeatedly demonstrated how sensitive valuations can be to clinical trial outcomes, particularly when late-stage assets represent significant contributors to future revenue expectations.

Pelacarsen Could Become a Major Growth Driver

Among the upcoming readouts, investors appear particularly focused on pelacarsen, an experimental therapy designed to reduce elevated lipoprotein(a), or Lp(a), a cardiovascular risk factor for which no approved targeted treatment currently exists.

The HORIZON trial is evaluating whether lowering Lp(a) can reduce the incidence of heart attacks and strokes. Success could position Novartis as the first company to commercialize a treatment addressing this previously underserved patient population, potentially creating an important long-term revenue opportunity.

Beyond statistical significance, investors and clinicians will also evaluate whether the treatment demonstrates clinically meaningful benefits that support widespread physician adoption, reimbursement, and long-term commercial success. At the same time, additional pipeline candidates targeting neurological and rare genetic diseases will remain closely watched as part of the company’s broader innovation strategy.

Looking ahead, Novartis’ upcoming clinical milestones are likely to carry greater influence on investor sentiment than quarterly earnings alone. Strong trial outcomes could reinforce confidence that the company can successfully replace revenue lost to future patent expirations, while weaker-than-expected results may challenge the premium valuation currently assigned to one of Europe’s largest pharmaceutical companies.